Skip to main content

Table 3 Clinical adverse event in the two arms of the study

From: A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire

Adverse event Artemisinin/naphtoquine Artemether/lumefantrine
  N = 62 % N = 61 %
Asthenia 1 1.6 1 1.6
Anorexia 3 4.8 1  
Nausea 1 1.6 3 4.8
Vomitting 1 1.6 3 4.8
Diarrhoea 2 3.2 1 1.6
Dizziness 2 3.2 1 1.6
Abdominal pain 1 1.6 2 3.3
Pruritus 1 1.6 0 0
  1. The most commonly reported and possibly drug-related adverse events to both combination therapies were effects on the gastrointestinal (abdominal pain, anorexia, nausea, diarrhoea and late vomiting) and central nervous system (dizziness)
  2. ETF = Early treatment failure LCF = Late clinical failure LPF = Late parasitological failure ACPR = Adequate Clinical and parasitological response. As shown in Table 2, the ACPR was 100% for AN and AL on day 14 after treatment. On day 28 cure rates were 100% (62 of 62) and 98.4% (60 of 61) for participants receiving AN and AL, respectively. When the efficacy results were corrected for PCR results, an ACPR of 100% was observed with AL (61/61). This difference between treatment arms was not statistically significant (p > 0.05)